{"product_id":"9781461420118","title":"A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities","description":"\u003ch1\u003eA Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities\u003c\/h1\u003e \u003ch2\u003ede Leon, Jose\u003c\/h2\u003e \u003cp\u003e\u003c\/p\u003e\u003cp\u003eEmotional, behavioral, and neuropsychiatric conditions are common in individuals with intellectual disabilities (IDs), most notably epilepsy, aggression, self-injurious behaviors, and bipolar and other mood disorders. Despite the prevalence of such problems, there is a scarcity in the literature of reliable information on medical treatments for those with IDs.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003ci\u003eA Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities\u003c\/i\u003e provides a detailed framework for prescribing for this challenging population. Featuring the most up-to-date information on factors that inform prescribing, the \u003ci\u003eGuide\u003c\/i\u003e addresses basic issues and controversies (e.g., the rift between evidence-based and personalized medicine) in treating adults with cognitive deficits. Clients' specific needs are emphasized in developing appropriate and effective pharmacological intervention for improved outcomes and quality of life. Drugs discussed in the \u003ci\u003eGuide\u003c\/i\u003e include carbamazepine, clonazepam, diazepam, ethosuximide, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lithium, lorazepam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, rufinamide,  tiagabine, topiramate, valproate, and zonisamide. For each of these compounds, the guidelines cover:\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eIndications for use; relative and absolute contraindications.\u003c\/li\u003e\n\u003cli\u003eAssessment during treatment; therapeutic drug monitoring; warning signs and symptoms for caretakers.\u003c\/li\u003e\n\u003cli\u003eDosage: administration; initial and maximum recommended dosage; modifications associated with drug-drug interactions, personal characteristics, and (where appropriate) genetic variations.\u003c\/li\u003e\n\u003cli\u003eAdverse drug reactions: common, relatively uncommon, and potentially lethal, plus risk of metabolic syndrome.\u003c\/li\u003e\n\u003cli\u003eGuidelines for discontinuation.\u003c\/li\u003e\n\u003cli\u003eReferences, tables, and drug utilization reviews.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003ci\u003eA Practitioner's Guide to PrescribingAntiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities\u003c\/i\u003e is an indispensable decision-making reference for psychiatrists, neuropsychologists, psychopharmacologists, neurologists, internists, and clinical psychologists.\u003c\/p\u003e \u003ch3\u003eDetails\u003c\/h3\u003e \u003cp\u003ePublished by: Springer\u003c\/p\u003e \u003cp\u003ePublication Date: 2012-03-02\u003c\/p\u003e \u003cp\u003eFormat: Paperback\u003c\/p\u003e \u003cp\u003eISBN-13: 9781461420118\u003c\/p\u003e \u003cp\u003eDOI: 10.1007\/978-1-4614-2012-5\u003c\/p\u003e \u003cp\u003eDimensions: 235cm x155cm\u003c\/p\u003e \u003cp\u003ePages: 507\u003c\/p\u003e ","brand":"Springer New York","offers":[{"title":"Default Title","offer_id":47404674416780,"sku":"9781461420118","price":98.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0710\/9545\/1788\/files\/9781461420118.jpg?v=1775815842","url":"https:\/\/lateknightbooks.com\/products\/9781461420118","provider":"Late Knight Books and Services, LLC","version":"1.0","type":"link"}